BAY-598 A selective chemical probe for SMYD2

This probe is available from Sigma, Cayman Chemical and Tocris.

The control may be requested by clicking here.

overview
Probe Negative control

 

BAY-598

 

BAY-369

SET  and  MYND  domain-containing  protein  2  (SMYD2)  is  a member  of  the  SMYD  family  of  protein  methyltransferases.  All  five members of this family (SMYD1–5) contain a conserved catalytic SET domain and a zinc-finger MYND motif. SMYD2 methylates both histone and non-histone proteins, including p53/TP53 and RB1 [1-3]. It specifically methylates histone H3 'Lys-4' (H3K4me) and dimethylates histone H3 'Lys-36' (H3K36me2) [1]. It has relatively higher methyltransferase activity on p53/TP53 and monomethylates 'Lys-370' of p53/TP53, leading to decreased DNA-binding activity and subsequent transcriptional regulation activity of p53/TP53. SMYD2 is over-expressed in esophageal squamous primary carcinomas and that over-expression correlates with poor patient survival [2].

A collaboration between Bayer and the SGC has resulted in the discovery of BAY-598 [4], a potent, peptide-competitive chemical probe for SMYD2. BAY-598 has a unique chemotype relative to the current SMYD2 chemical probe LLY-507 [5] and inhibitors [6,7]. BAY-598 inhibits in vitro methylation of p53K370 with IC50 = 27 nM and has more than 100-fold selectivity over other histone methyltransferases and other non-epigenetic targets. BAY-598 inhibits the methylation of p53K370 in cells with IC50 < 1 µM. (Further to this, BAY-598 has properties that are compatible with in vivo experiments.) A control compound, BAY-369, has also been developed. BAY-369 inhibits the in vitro methylation of p53K370 with IC50 > 70 micromolar.

properties
Probe Negative control

 

BAY-598

 

BAY-369

Physical and chemical properties for BAY-598
Molecular weight524.1
Molecular formulaC22H20Cl2F2N6O3
MollogP3.881
PSA86.02
No. of chiral centres1
No. of rotatable bonds11
No. of hydrogen bond acceptors7
No. of hydrogen bond donors2
Physical and chemical properties for BAY-369 (racemate)
Molecular weight456.2
Molecular formulaC22H22F2N6O3
MollogP2.573
PSA86.02
No. of chiral centres1
No. of rotatable bonds11
No. of hydrogen bond acceptors7
No. of hydrogen bond donors2


SMILES:
BAY-598: CCN([C@H]1CN(N=C1C2=CC(Cl)=C(Cl)C=C2)/C(NC3=CC=CC(OC(F)F)=C3)=N\C#N)C(CO)=O
BAY-369: CCN(C(CO)=O)C1CN(N=C1C2=CC=CC=C2)/C(NC3=CC=CC(OC(F)F)=C3)=N\C#N

InChI:
BAY-598: InChI=1S/C22H20Cl2F2N6O3/c1-2-31(19(34)11-33)18-10-32(30-20(18)13-6-7-16(23)17(24)8-13)22(28-12-27)29-14-4-3-5-15(9-14)35-21(25)26/h3-9,18,21,33H,2,10-11H2,1H3,(H,28,29)/t18-/m0/s1

BAY-369: InChI=1S/C22H22F2N6O3/c1-2-29(19(32)13-31)18-12-30(28-20(18)15-7-4-3-5-8-15)22(26-14-25)27-16-9-6-10-17(11-16)33-21(23)24/h3-11,18,21,31H,2,12-13H2,1H3,(H,26,27)

InChIKey:
BAY-598:OTTJIRVZJJGFTK-SFHVURJKSA-N
BAY-369: OEYJKIQNPLLSFW-UHFFFAOYSA-N

selectivity profile

BAY-598 is a potent SMYD2 inhibitor and acts via a peptide competitive mechanism of action.

Selectivity

Selectivity of BAY-598 within methyltransferase family

in vitro potency
cell based assay data

Cellular activity

BAY-598 is a potent inhibitor of p53 K370 methylation in cells

references

1.Brown MA, Sims RJ 3rd, Gottlieb PD, Tucker PW (2006) Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex. Mol Cancer 5: 26.

2.Komatsu S, Imoto I, Tsuda H, Kozaki KI, Muramatsu T, et al. (2009) Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma. Carcinogenesis 30: 1139-1146.

3.Cho HS, Hayami S, Toyokawa G, Maejima K, Yamane Y, et al. (2012) RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation. Neoplasia 14: 476-486.

4.Eggert E, Hillig RC, Köhr S, Stöckigt D, Weiske J, Barak N,, et al. (2016) Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2  J Med Chem

5.Nguyen H, Allali-Hassani A, Antonysamy S, Chang S, Chen LH, et al. (2015) LLY-507, a Cell-Active, Potent and Selective Inhibitor of Protein Lysine Methyltransferase SMYD2. 290: 13641-53.

6.Ferguson AD, Larsen NA, Howard T, Pollard H, Green I, et al. (2011) Structural Basis of Substrate Methylation and Inhibition of SMYD2. Structure 19: 1262-73.

7.Sweis RF, Wang Z, Algire M, Arrowsmith CH, Brown PJ, et al. (2015) Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2. ACS Med Chem Lett. 6: 695-700.

pk properties
co-crystal structures

Please wait whilst the interactive viewer is loaded!

Main features

synthetic schemes
materials and methods

BI-9564 A chemical probe for BRD9 and BRD7

This probe is available from Tocris , Sigma and  Cayman Chemical.

BI-9564 and a negative control are available from opnMe.com.

overview
Probe

BI-9564

Biology of Probe and Target

BRD7 and BRD9 are related bromodomain-containing proteins that form a small sub-branch of the bromodomain family tree (1). Human BRD9 contains a single bromodomain and has five isoforms that are produced by alternative splicing. Little is known about BRD9 function; BRD7 has been reported to act both as coactivator, for example for some p53 target genes and as corepressor, negatively regulating the GSK3B phosphotransferase activity. Both proteins have been implicated in chromatin remodelling as part of the SWI/SNF complex. BRD7 has been described as transcriptional corepressor that down-regulates the expression of target genes. Its binding to promoters also leads to increased histone H3 acetylation at 'Lys-9' (H3K9ac).

Phylogenetic tree of bromodomains and detailed view at the sub-branch of related bromodomain-containing proteins BRD7/9.

BI-9564 is a BRD9/7 specific inhibitor that has been developed in collaboration with Boehringer-Ingelheim. This probe was discovered through fragment-based screening and optimized by structure guided design.
BI-9564 binds to BRD9 with a higher potency (KD of 14 nM) than to BRD7 (KD of 239nM) as determined ITC, with CECR2 as the only off-target in vitro. BI-9564 is >30-fold selective against other non-Class IV bromodomains and negative against BET family members. BI-9564 does not significantly affect 324 kinases. BI-9564 is highly potent in cells and shows anti-proliferative activity in particular cell type.

Potency

BI-9564 binds to BRD9 with a higher affinity (KD of 14 nM, ITC) than to BRD7 (KD of 239nM, ITC), is completely negative on BET family members (>100 µM by alpha screen) and demonstrates cellular activity by FRAP on BRD9 and BRD7 at 0.1 µM and 1 µM, respectively.

BRDKd/nM (ITC)IC50/nM (Alpha Screen)
BRD72393410
BRD91475
CECR2258NT
(NT = Not Tested)

Selectivity

Alpha screen confirmed BI-9564 as a potent inhibitor of BRD9 (IC50 of 75 nM). BI-9564 is very selective against other non-Class IV bromodomains, including the BETs. The only off-target effect was determined against CECR2 (18-fold selective), but not in cells (at 1 µM, FRAP). BI-9564 shows no significant off-target pharmacology against a panel of 324 kinases at concentrations less than 5 µM and is functionally active in cellular assays.

Cellular Activity

FRAP assay demonstrate that BI-9564 is able to disrupt the binding of BRD7 and BRD9 to chromatin in cells at 1 µM and 0.1 µM, respectively. BI-9564 shows no cellular inhibition of CECR2 at 1 µM.

In vitro Activity

In a broad cancer cell line panel treatment with BI-9564 resulted in selective growth inhibition of EOL-1 AML cells both in vitro (EC50 = 800 nM) and in a disseminated mouse model of AML (180 mg/kg/day).

properties
4-(4-((dimethylamino)methyl)-2,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one
Physical and chemical properties
Molecular weight353.422
Molecular formulaC20H23N3O3
IUPAC name4-(4-((dimethylamino)methyl)-2,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one
clogP1.5
PSA54.9
No. of chiral centres0
No. of rotatable bonds5
No. of hydrogen bond acceptors5
No. of hydrogen bond donors0
StorageStable as solid in the dark at -20°C. NB making aliquots rather than freeze-thawing is recommended
DissolutionSoluble in DMSO
  • SMILES:
  • CN(CC1=CC(OC)=C(C=C1OC)C(C2=C3C=NC=C2)=CN(C3=O)C)C
  • InChI:
  • InChI=1S/C20H23N3O3/c1-22(2)11-13-8-19(26-5)15(9-18(13)25-4)17-12-23(3)20(24)16-10-21-7-6-14(16)17/h6-10,12H,11H2,1-5H3
  • InChIKey:
  • BJFSUDWKXGMUKA-UHFFFAOYSA-N
selectivity profile

Temperature Shift Assay

Selectivity profile of BI-9564 using temperature shift assay at 10µM.

Isothermal Titration Calorimetry (ITC)

Binding affinity of BI-9564 towards BRD 7 and BRD 9 measured by ITC.

in vitro potency
cell based assay data

Fluorescence Recovery After Photobleaching (FRAP) Assay

Half-times of fluorescence recovery (t1/2) after photo-bleaching measured for BRD9, BRD7 and CECR2 treated either with or without SAHA and BI-9564 at indicated concentrations.

references

Work on this probe has been published in ‘Structure-based design of an in vivo active selective BRD9 inhibitor’.

  1. Muller S. et al., Bromodomains as therapeutic targets. Exp Rev Mol Med. 2011, 13, e29.
  2. Filippakopoulos P. et al., Histone recognition and largescale structural analysis of the human bromodomain family. Cell. 2012, 149, 214-231.
  3. Whitehouse I. et al., Nucleosome mobilization catalysed by the yeast SWI/SNF complex. Nature 1999, 400, 784–787.
pk properties
co-crystal structures
synthetic schemes
materials and methods

Isothermal Titration Calorimetry (ITC)

All calorimetric experiments were performed on a VP-ITC micro-calorimeter (MicroCalTM, LLC Northampton, MA). Protein solutions were buffer exchanged by gel filtration or dialysis into buffer (20 mM Hepes pH 7.5, 150 mM NaCl, and 0.5 mM tris (2-carboxyethyl) phosphine (TCEP). All measurements were carried out at 288.15 K. All injections were performed using an initial injection of 2 µL followed by injections of 8 µL. The data were analysed with the MicroCal ORIGIN software package employing a single binding site model. The first data point was excluded from the analysis. 

Temperature shift assay

Thermal melting experiments were carried out using a Stratagene Mx3005p Real Time PCR machine (Agilent Technologies). BI-9564 was added at a final concentration of 10 µM. SYPRO Orange (Molecular Probes) was added as a fluorescence probe at a dilution of 1:1000 as described (2).

Fluorescence Recovery After Photobleaching (FRAP) Assay

U2OS cells were transfected (Fugene HD; Roche) with mammalian over- expression constructs encoding GFP fused to the N-terminus of full length BRD9, Brd7 or CECR2, respectively. Mutant proteins mutating the conserved Asn to Phe or Ala were generated as described in (3). The following mutations were introduced: N140A for human CECR2, N211F for mouse Brd7 and N163F for human BRD9. The imaging systemconsisted of a Zeiss LSM 710 laser-scanning and control system (Zeiss) coupled to an inverted Zeiss Axio Observer.Z1 microscope equipped with a high-numerical-aperture (N. A. 1.3) 40 x oil immersion objective (Zeiss). Samples were placed in an incubator chamber in order to maintaining temperature and humidity. FRAP and GFP fluorescence imaging were both carried out with an argon-ion laser (488 nm) and with a PMT detector set to detect fluorescence between 500-550 nm. Once an initial scan had been taken, a region of interest corresponding to approximately 50 % of the entire GFP positive nucleus was empirically selected for bleaching. A time lapse series was then taken to record GFP recovery using 1% of the power used for bleaching. The image datasets and fluorescence recovery data were exported from ZEN 2009, the microscope control software, into Origin to determine the average half-time for full recovery for 10-20 cells per treatment point.

02.04.2015

SGC members talk about open access impact on science and drug discovery in 27 languages

by: SGC

SGC scientists come from countries all over the world to do drug discovery research at our laboratories in Canada, UK and Brazil.

Watch videos of SGC members talking about SGC science and open access in 27 different languages like Arabic, Mandarin, Portuguese and Russian, to name a few: http://www.thesgc.org/sgclanguages

SGC’s open access policy of sharing knowledge and research results without restrictions has helped accelerate the discovery of new medicines for many debilitating diseases such as cancer.

10.03.2015

Open-Source Scientific Research Comes to Brazil

by: SGC

Open-access research into drug discovery has arrived in South America, with a ground-breaking collaboration between leading scientists in North America, Europe and Brazil to provide completely free and open research results to the world.

A $4.3-million (USD) grant from the São Paulo Research Foundation (FAPESP) plus an in-kind contribution of US$ 1.9 million by The University of Campinas (UNICAMP), totalling US$ 6,2 million, will establish Brazil’s first open-access research facility, the Protein Kinase Chemical Biology Centre at the UNICAMP in Brazil.

GSK484 A chemical probe for PAD-4 (Protein-arginine deiminase type-4)

The probe GSK484 (hydrochloride) is available from Cayman Chemical and Sigma.

The negative control GSK106 (hydrochloride) is available from Cayman Chemical.

overview
Probe Negative control

 

GSK484

 

GSK106

PAD4 is a calcium-dependent enzyme which catalyses the transformation of protein arginine residues into citrulline, with the release of ammonia. PAD4-dependent citrullination/deimination of histones plays a key role in the histone code and is predicted to manifest with wide-ranging transcriptional and structural functions, including recently-discovered roles in the regulation of stem cell maintenance (1). In addition to a growing rationale in oncology, PAD4 has strong associations with multiple immune and inflammatory processes.  For example, in rheumatoid arthritis the enzyme citrullinates joint proteins to break tolerance and provoke autoimmunity, with antibodies against these citrullinated epitopes (and against PAD4 itself) representing a diagnostic hallmark of the disease.  In addition, PAD4 is known to promote profound chromatin decondensation during the innate immune response to infection in neutrophils by mediating formation of neutrophil extracellular traps (NETs). This is an enigmatic and exciting field where initially proposed roles for NETs in trapping pathogens for host-defence purposes (2) have been extended to demonstrate that unrestrained NETosis may be crucial for pathological deep venous thrombosis (3) ischemia/reperfusion injury (4), systemic lupus erythematosis (5), small vessel vasculitis (6) and also in rheumatoid arthritis (7).

GlaxoSmithKline has developed a PAD4-specific probe (8), namely GSK484 and has made it available as part of the SGC epigenetics initiative. GSK484 potently binds to the low-calcium form of PAD4 in a reversible manner (IC50 of 50 nM) and appears to be competitive with substrate. GSK106 is a related control molecule (IC50 > 100 µM) which offers important confirmation of PAD4-specific effects. Detailed crystallography work with this compound series has additionally demonstrated binding to a new conformation of the PAD4 active site where key residues are re-ordered to form a β-hairpin. GSK484’s selectivity for PAD4 over PAD1-3 was shown in cells and also confirmed with recombinant enzymes. This probe is an inhibitor of cellular citrullination in primary neutrophils, and further phenotypic profiling has confirmed its ability to inhibit NET formation in both mouse and human neutrophils. GSK484 exhibits favourable pharmacokinetic profiles, with low-moderate clearance, and good volume of distribution and half-life in mouse and rat, and has suitable a PK profile for use as a potential in vivo tool.

properties
Probe Negative control

 

GSK484

 

GSK106

Physical and chemical properties for GSK484
Molecular weight473.2
Molecular formulaC27H31N5O3
IUPAC name(3-amino-4-hydroxy-piperidin-1-yl)-(8-(7-(cyclopropyl-methyl)-7-aza-bicyclo[4.3.0]nona-1(6),2,4,8-tetraen-8-yl)-5-methoxy-7-methyl-7,9-diaza-bicyclo[4.3.0]nona-1,3,5,8-tetraen-3-yl)-methanone
MollogP2.665
PSA71.66
No. of chiral centres2
No. of rotatable bonds6
No. of hydrogen bond acceptors6
No. of hydrogen bond donors3
Physical and chemical properties for GSK106 (Negative Control)
Molecular weight401,51
Molecular formulaC24H27N5O
IUPAC name(3-aminopiperidin-1-yl)(2-(1-ethyl-1H-indol-2-yl)-1-methyl-1H-benzo[d]imidazol-6-yl)methanone
MollogP3.13
PSA47.78
No. of chiral centres1
No. of rotatable bonds4
No. of hydrogen bond acceptors4
No. of hydrogen bond donors3

SMILES:
GSK484: CN1C2=C(OC)C=C(C(N3C[C@@H]([C@@H](CC3)O)N)=O)C=C2N=C1C4=CC5=C(C=CC=C5)N4CC6CC6
GSK106: CCN1C(C2=NC3=CC=C(C(N4CCCC(N)C4)=O)C=C3N2C)=CC5=C1C=CC=C5

InChI:
GSK484: InChI=1S/C27H31N5O3/c1-30-25-20(11-18(13-24(25)35-2)27(34)31-10-9-23(33)19(28)15-31)29-26(30)22-12-17-5-3-4-6-21(17)32(22)14-16-7-8-16/h3-6,11-13,16,19,23,33H,7-10,14-15,28H2,1-2H3/t19-,23+/m0/s1

GSK106: InChI=1S/C24H27N5O/c1-3-29-20-9-5-4-7-16(20)13-22(29)23-26-19-11-10-17(14-21(19)27(23)2)24(30)28-12-6-8-18(25)15-28/h4-5,7,9-11,13-14,18H,3,6,8,12,15,25H2,1-2H3

InChIKey:
GSK484: BDYDINKSILYBOL-WMZHIEFXSA-N
GSK106: ZDERDCQPANYYQW-UHFFFAOYSA-N

selectivity profile
in vitro potency
cell based assay data
references
  1. Slade DJ, Horibata S, Coonrod SA, Thompson PR, Bioessays, 2014, 36(8):736-740.
  2. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A, Science, 2004 303(5663):1532-5.
  3. Martinod K, Demers M, Fuchs TA, Wong SL, Brill A, Gallant M, Hu J, Wang Y, Wagner DD. Proc Natl Acad Sci U S A. 2013, 110(21):8674-9.
  4. Savchenko AS, Borissoff JI, Martinod K, De Meyer SF, Gallant M, Erpenbeck L, Brill A, Wang Y, Wagner DD, Blood, 2014, 123(1):141-8.
  5. Hakkim A, Fürnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, Herrmann M, Voll RE, Zychlinsky A., Proc Natl Acad Sci USA., 2010, 107(21):9813-8.
  6. Ohlsson SM2, Ohlsson S, Söderberg D, Gunnarsson L, Pettersson Å, Segelmark M, Hellmark T., Clin Exp Immunol., 2014, 176(3):363-72.
  7. Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, Gizinski A, Yalavarthi S, Knight JS, Friday S, Li S, Patel RM, Subramanian V, Thompson P, Chen P, Fox DA, Pennathur S, Kaplan MJ., Sci Transl Med., 2013, 5(178):178ra40.
  8. Lewis HD, Liddle J, Coote JE, Atkinson SJ, Barker MD, Bax BD, Bicker KL, Bingham RP, Campbell M, Chen YH, Chung CW, Craggs PD, Davis RP, Eberhard D, Joberty G, Lind KE, Locke K, Maller C, Martinod K, Patten C, Polyakova O, Rise CE, Rüdiger M, Sheppard RJ, Slade DJ, Thomas P, Thorpe J, Yao G, Drewes G, Wagner DD, Thompson PR, Prinjha RK, Wilson DM., Nat Chem Biol. 2015,11(3):189-191.
pk properties

in vivo PK Profile of GSK484

GSK Data - shared with SGC February y2016.
All animal studies were ethically reviewed and carried out in accordance with Animals (Scientific Procedures) Act 1986 and the GSK Policy on the Care, Welfare and Treatment of Animals.

co-crystal structures
synthetic schemes
materials and methods
20.02.2015

SGC Toronto hosts an interactive workshop on EZH2 inhibitors to promote sharing of latest advances in the field

by: SGC

On Monday February 9th, 2015, SGC Toronto hosted the one-day workshop EZH2 inhibitors: Target Validation through Chemical Biology focusing on discussion and sharing of data around the use of inhibitors of EZH2.

“EZH2 is a major regulator of epigenetic states and an important clinical target in oncology”, explained Dr. Cheryl Arrowsmith, Chief Scientist of SGC Toronto.

04.02.2015

Merck Announces a Contribution of $7.5 Million to the Structural Genomics Consortium (SGC) Toronto

by: SGC

"This morning at MaRS Discovery District, Merck confirmed its commitment to research and innovation with a $7.5 million contribution to the Structural Genomics Consortium Toronto. (From left to right) Dr. Ronan O'Hagan, Dr. Aled Edwards, The Honourable Reza Moridi, Mr. Chirfi Guindo and Ms. Jennifer Chan. (CNW Group/Merck)".

PFI-4 A chemical probe for BRPF1B

This probe is available from Sigma and Cayman Chemical.

overview
Probe

PFI-4

Biology of target and probe

A chemical probe for the bromodomains of the BRPF (BRomodomain and PHD Finger containing) family of proteins (BRPF1/2/3) has been discovered by the SGC. BRPF1, BRPF2 (BRD1) and BRPF3 are scaffolding proteins, assembling HAT complexes of the MOZ/MORF family (MOZ, Ybf2/Sas3, Sas2, and Tip60) (1). These MYST complexes have a tetrameric core containing BRPF, the tumour suppressor ING and Eaf6/EPC (enhancer of polycomb)-related scaffold subunits. MYST complexes play crucial roles in DNA repair, recombination, and replication as well as in transcription activation (2,3). MOZ is frequently translocated in AML (acute myeloid leukemia) and is required for HSC proliferation (4). Two BRPF1 isoforms (isoform A and B) can be generated by alternative splicing. In contrast to BRPF1B, the isoform A harbours a residue insertion in the ZA-loop that prevents binding to acetylated histone peptides (5).

Phylogenetic tree of bromodomains and detailed view at the BRPF family.

A chemical probe for the bromodomain of the BRPF1B has been developed in collaboration with Pfizer. PFI-4 specifically binds to BRPF1B with a KD of 13 nM as determined by ITC. It reduces recovery time in U2OS cells transfected with a BRPF1B triple BRD construct with a nuclear localisation signal (NLS) in the FRAP assay at 500 nM, while showing no effect on BRPF1A. A NanoBRETTM cellular target engagement assay evaluating the interaction of BRPF1B with histones suggested IC50 of 240 nM for PFI-4.

Potency Against Target Family

BRPFKd/nM (ITC)IC50/nM (Alpha Screen)TM Shift °C
BRPF1B131729.4
BRPF2 (BRD1)77536002

PFI-4 specifically binds to BRPF1B with a KD of 13 nM as determined by ITC.

Selectivity

PFI-4 induced significant temperature shifts for BRPF1B (ΔTm of 9.4 °C). Weak interactions (2.0 °C) were also observed for BRD1 and CECR2, however the binding to BRD1 shows 60-fold selectivity with a KD of 775 nM and IC50 of 3600 nM. CECR2 was the only detected off-target outside family IV with only 2350 nM affinity, thus showing 167-fold selectivity.

Dosage

Use PFI-4 at concentrations of around 1 µM. PFI-4 is non-toxic up to 50 μM in U2OS cells.

Cellular Activity

In a FRAP assay PFI-4 recovery time in U2OS cells transfected with a BRPF1B triple BRD construct with a nuclear localisation signal (NLS) at 500 nM. PFI-4 had no effect on the recovery time of BRPF1A.
In a NanoBRETTM cellular target engagement assay using isolated BRPF1B BRD with NLS and Halo-tagged histone H3.3 BRPF1B isoform showed a dose-dependent displacement from histone H3.3, with estimated cellular IC50 of 240 μM. No PFI-4 had no effect on the BRPF1A isoform.

In vitro Activity

PFI-4 induces re-localisation of BRPF1B resulting in a more uniform distribution in nuclei and expression in nucleoli as well as a greater expression in cytoplasm PFI-4 has no effect on the BRPF1A isoform.

properties
Probe

PFI-4

Physical and chemical properties
Molecular weight380.45
Molecular formulaC21H24N4O3
IUPAC nameN-(1,3-dimethyl-2-oxo-6-(pyrrolidin-1-yl)-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-2-methoxybenzamide
clogP2.23
PSA65.12 
No. of chiral centres0
No. of rotatable bonds5
No. of hydrogen bond acceptors4
No. of hydrogen bond donors1
StorageStable as solid in the dark at -20°C. NB making aliquots rather than freeze-thawing is recommended
DissolutionSoluble in DMSO
  • SMILES:
  • CN1C2=CC(NC(C3=CC=CC=C3OC)=O)=C(N4CCCC4)C=C2N(C)C1=O
  • InChI:
  • InChI=1S/C21H24N4O3/c1-23-17-12-15(22-20(26)14-8-4-5-9-19(14)28-3)16(25-10-6-7-11-25)13-18(17)24(2)21(23)27/h4-5,8-9,12-13H,6-7,10-11H2,1-3H3,(H,22,26)
  • InChIKey:
  • QCIJLRJBZDBVDB-UHFFFAOYSA-N
selectivity profile

Dissociation constants of PFI-4 and BRDF1B or CECR2 interactions measured by isothermal titration calorimetry (ITC).

The temperature shifts mapped onto the phylogenetic tree using red circles corresponding to ΔTm as indicated in the figure.

in vitro potency
cell based assay data

Thermal-stability of BRPF1A/B determined by CESTA at 1 µM PFI-4.


 

BRET assay using BRPF1A or BRPF1B-BRD with NLS (nuclear localisation signal) and H3.3 after treatment with PFI-4.


Half-times of fluorescence recovery (t1/2) after photo-bleaching measured for BRPF1B and BRPF1A treated either with or without SAHA and PFI-4 at indicated concentrations.


Confocal pictures of U2OS cells transfected with triple BRD–GFP construct of BRPF1B or BRPF1A containing NLS treated either with or without 1 μM PFI-4.

pk properties
co-crystal structures
synthetic schemes
materials and methods

Isothermal Titration Calorimetry (ITC)

All calorimetric experiments were performed on a VP-ITC micro-calorimeter (MicroCalTM, LLC Northampton, MA). Protein solutions were buffer exchanged by gel filtration or dialysis into buffer (20 mM Hepes pH 7.5, 150 mM NaCl, and 0.5 mM tris (2-carboxyethyl) phosphine (TCEP). All measurements were carried out at 288.15 K. All injections were performed using an initial injection of 2 µL followed by injections of 8 µL. The data were analysed with the MicroCal ORIGIN software package employing a single binding site model. The first data point was excluded from the analysis. 

Temperature shift assay

Thermal melting experiments were carried out using a Stratagene Mx3005p Real Time PCR machine (Agilent Technologies). PFI-4 was added at a final concentration of 10 µM. SYPRO Orange (Molecular Probes) was added as a fluorescence probe at a dilution of 1:1000 as described (6).

AlphaScreen Assay

Assays were performed as described previously with minor modifications (7). All reagents were diluted in 25 mM HEPES, 100 mM NaCl, 0.1 % BSA, pH 7.4 supplemented with 0.05 % CHAPS and allowed to equilibrate to room temperature prior to addition to plates. An 11-point 1:2.0 serial dilutions of the ligands was prepared on lowvolume 384-well plates (ProxiPlateTM-384 Plus, PerkinElmer, USA), using LabCyte Eco liquid handler. Plates filled with 5 µL of the assay buffer followed by 7 µL of biotinylated peptide [H-YSGRGKacGGKacGLGKacGGAKacRHRK(Biotin)-OH for BRD1, BRD4, BRPF1B and BRPF3 or YQTARKSTGGK(ac)APRKQLATKAK(biotin)-OH for TIF1α] and Histagged protein to achieve final assay concentrations of 25-100 nM depending on the dose-response curve for each individual protein. Plates were sealed and incubated for a further 30 minutes, before the addition of 8 µM of the mixture of streptavidin-coated donor beads (12.5 µg/mL) and nickel chelate acceptor beads (12.5 µg/mL) under low light conditions. Plates were foil-sealed to protect from light, incubated at room temperature for 60 minutes and read on a PHERAstar FS plate reader (BMG Labtech, Germany) using an AlphaScreen 680 excitation/570 emission filter set. IC50 values were calculated in Prism 5 (GraphPad Software, USA) after normalization against corresponding DMSO controls.

Fluorescence Recovery After Photobleaching (FRAP) Assay

FRAP studies were performed using U20S cells expressing GFP-bound BRPF1a or BRPF1B (triple bromodomain). Six hours after transfection 2.5 µM SAHA (to increase global histone acetylation) was added and cells were treated with 1 µM or 5 µM of PFI-4 1 hour before imaging and half recovery times from the fluorescence signal of the bleached U2OS nuclei were plotted.

NanoBRET

U2OS cells were co-transfected with Histone H3.3-HaloTag and NanoLuc-BRPF1. Twenty hours post-transfection cells were collected, washed with PBS, and exchanged into media containing phenol red-free DMEM and 4% FBS in the absence (control sample) or the presence (experimental sample) of 100 nM NanoBRET 618 fluorescent ligand (Promega). Cells were then treated with an increasing dose of OF-1. Five minutes prior to reading, NanoBRET furimazine substrate (Promega) was added to both control and experimental samples and plates were read on a CLARIOstar (BMG) equipped with 450/80 nm bandpass and 610 nm longpass filters with a 0.5 sec reading setting. A corrected BRET ratio was calculated and is defined as the ratio of the emission at 610 nm/450 nm for experimental samples (i.e. those treated with NanoBRET fluorescent ligand) subtracted by and the emission at 610 nm/450 nm for control samples (not treated with NanoBRET fluorescent ligand). BRET ratios are expressed as milliBRET units (mBU), where 1 mBU corresponds to the corrected BRET ratio multiplied by 1000. Relative IC50 values were estimated by non-linear regression analysis of (log) concentration of each inhibitor versus milliBRET ratios (GraphPad Prism).

NI-57 A chemical probe for BRPF bromodomains

This probe is available from SigmaTocris and Cayman Chemical.

overview
Probe

NI-57

Biology of probe and target

A collaboration between the SGC and University College London (UCL) has resulted in the discovery of NI-57 as a chemical probe for the bromodomains of the BRPF (BRomodomain and PHD Finger) family of proteins (BRPF1/2/3).
BRPF1, BRPF2 (BRD1) and BRPF3 are scaffolding proteins, assembling HAT complexes of the MOZ/MORF family (MOZ, Ybf2/Sas3, Sas2, and Tip60) (1). These MYST complexes have a tetrameric core containing BRPF, the tumour suppressor ING and Eaf6/EPC (enhancer of polycomb)-related scaffold subunits. MYST complexes play crucial roles in DNA repair, recombination, and replication as well as in transcription activation (2,3). MOZ is frequently translocated in AML (acute myeloid leukemia) and is required for HSC proliferation (4).
Two BRPF1 isoforms (isoform A and B) can be generated by alternative splicing. In contrast to BRPF1B, the isoform A harbours a residue insertion in the ZA-loop that prevents binding to acetylated histone peptides (5).

Phylogenetic tree of bromodomains and detailed view at the BRPF family.

NI-57 is a potent inhibitor of the bromodomain of the BRPFs and binds to BRPF1B with a KD of 31 nM (ITC), to BRPF2 with a KD of 108 nM (ITC) and to BRPF3 KD of 408 nM (ITC). NI-57 is very selective against other non-Class IV bromodomains, including the BETs, as measured by both biophysical and biochemical methods. The closest off-target effects are against BRD9 (32-fold selective). NI-57 shows accelerated FRAP recovery at 1 µM in the BRPF2 FRAP assay preventing binding of full-length BRPF2 to chromatin.

Potency Against Target Family

NI-57 is a chemical probe with potent binding affinity for BRPF1 (KD of 31 nM), BRPF2 (KD of 108 nM) and to BRPF3 (KD of 408 nM) with good selectivity over BRD9 (KD of 1 μM) and BRD4 (KD of 3.9 μM) as determined by isothermal titration calorimetry (ITC). Alpha screen biochemical assay confirmed NI-57 as a potent inhibitor of BRPF1 (IC50 of 114 nM). No off targets were identified for NI-57 outside the BRD family.

BromodomainKd/nM (ITC)IC50/nM (Alpha Screen)TM Shift °C
BRPF1B3111410.7±0.3
BRPF2 (BRD1)1106195.6±0.1
BRPF341010105.3±0.3
BRD9100044003.1±0.7
BRD4(1)3900>10,0000.8±0.6

Selectivity

NI-57 showed significant selectivity for BRPF1/2/3 binding by DSF (differential scanning fluorimetry). NI-57 is very selective against other non-Class IV bromodomains, including the BETs, as measured by both biophysical and biochemical methods. The closest off-target effects were determined against BRD9 (32-fold selective). NI-57 shows minimal off-target pharmacology against a panel of GPCRs, ion channels, and enzymes and is functionally active in cellular assays.

Dosage

We recommend to use NI-57 at concentrations of up to 1 µM and use the BRPF inhibitor OF-1 in parallel to confirm the result.

Cellular Activity

NI-57 increases thermal stability in the CETSA of full length BRPF1B but not of the BRPF1A isoform.
NI-57 induces dose-dependent displacement of BRPF1B but not of the BRPF1A isoform from histone H3.3 in NanoBRETTM assay with estimated IC50 values of 0.07 μM.
In a FRAP assay BRD1 as well as BRPF1B show reduced recovery time for the displacement of full-length from chromatin in the presence of NI-57.

In vitro Activity

NI-57 inhibits RANKL/MCSF induced differentiation of primary human monocytes into osteoclasts.

properties
Probe

NI-57

Physical and chemical properties
Molecular weight383.42
Molecular formulaC19H17N3O4S
IUPAC name4-cyano-N-(1,3-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)-2-methoxybenzenesulfonamide
logP2.05
PSA99.5
No. of chiral centres0
No. of rotatable bonds5
No. of hydrogen bond acceptors5
No. of hydrogen bond donors1
StorageStable as solid in the dark at -20°C. NB making aliquots rather than freeze-thawing is recommended
DissolutionSoluble in DMSO
  • SMILES:
  • CC1=CC2=C(N(C)C1=O)C=CC(NS(=O)(C3=C(OC)C=C(C#N)C=C3)=O)=C2
  • InChI: 
  • InChI=1S/C19H17N3O4S/c1-12-8-14-10-15(5-6-16(14)22(2)19(12)23)21-27(24,25)18-7-4-13(11-20)9-17(18)26-3/h4-10,21H,1-3H3
  • InChIKey:
  • UEMQPCYDWCSVCU-UHFFFAOYSA-N
selectivity profile

Thermal Shift Assay

Selectivity profile of NI-57 using temperature shift assay. Temperature shifts ΔTm are indicated by red circles with increasing radii for higher Tm as described in the legend.

CEREP Screen

NI-57 (10 µm) was screened against a panel of 55 ligand receptors, ion channels and transports using an established and widely utilized commercial assay platform (ExpresSProfile; CEREP, Paris, FRANCE).

in vitro potency
cell based assay data

CESTA

Thermal-stability of BRPF1A/B determined by CESTA upon application of NI-57.

Re-location of BRPF1B to nucleolus and some ‘leak- out’ to cytoplasm in evidence upon compound treatment.

NI-57 attenuates osteoclastogenesis as seen when primary human monocytes (isolated from human cone blood via CD14+bead isolation) were cultured with MCSF (6 days) and the cells then treated with RANKL-/+ followed by NI-57 for at least 14 days. IF was performed with VNR (red), F-Actin (green) and DAPI to visualize the possible bone-resorbing cells

pk properties
co-crystal structures
synthetic schemes
materials and methods

Isothermal Titration Calorimetry (ITC)

All calorimetric experiments were performed on a VP-ITC micro-calorimeter (MicroCalTM, LLC Northampton, MA). Protein solutions were buffer exchanged by gel filtration or dialysis into buffer (20 mM Hepes pH 7.5, 150 mM NaCl, and 0.5 mM tris (2-carboxyethyl) phosphine (TCEP). All measurements were carried out at 288.15 K. All injections were performed using an initial injection of 2 µL followed by injections of 8 µL. The data were analysed with the MicroCal ORIGIN software package employing a single binding site model. The first data point was excluded from the analysis. 

Temperature shift assay

Thermal melting experiments were carried out using a Stratagene Mx3005p Real Time PCR machine (Agilent Technologies). OF-1 was added at a final concentration of 10 µM. SYPRO Orange (Molecular Probes) was added as a fluorescence probe at a dilution of 1:1000 as described (6).

AlphaScreen Assay

Assays were performed as described previously with minor modifications (7). All reagents were diluted in 25 mM HEPES, 100 mM NaCl, 0.1 % BSA, pH 7.4 supplemented with 0.05 % CHAPS and allowed to equilibrate to room temperature prior to addition to plates. An 11-point 1:2.0 serial dilutions of the ligands was prepared on lowvolume 384-well plates (ProxiPlateTM-384 Plus, PerkinElmer, USA), using LabCyte Eco liquid handler. Plates filled with 5 µL of the assay buffer followed by 7 µL of biotinylated peptide [H-YSGRGKacGGKacGLGKacGGAKacRHRK(Biotin)-OH for BRD1, BRD4, BRPF1B and BRPF3 or YQTARKSTGGK(ac)APRKQLATKAK(biotin)-OH for TIF1α] and Histagged protein to achieve final assay concentrations of 25-100 nM depending on the dose-response curve for each individual protein. Plates were sealed and incubated for a further 30 minutes, before the addition of 8 µM of the mixture of streptavidin-coated donor beads (12.5 µg/mL) and nickel chelate acceptor beads (12.5 µg/mL) under low light conditions. Plates were foil-sealed to protect from light, incubated at room temperature for 60 minutes and read on a PHERAstar FS plate reader (BMG Labtech, Germany) using an AlphaScreen 680 excitation/570 emission filter set. IC50 values were calculated in Prism 5 (GraphPad Software, USA) after normalization against corresponding DMSO controls.

Fluorescence Recovery After Photobleaching (FRAP) Assay

FRAP studies were performed using U20S cells expressing full-length BRPF2 (BRD1). Six hours after transfection 2.5 µM SAHA (to increase global histone acetylation) was added and cells were treated with 1 µM or 5 µM of OF-1 1 hour before imaging and half recovery times from the fluorescence signal of the bleached U2OS nuclei were plotted.

NanoBRET

U2OS cells were co-transfected with Histone H3.3-HaloTag and NanoLuc-BRPF1. Twenty hours post-transfection cells were collected, washed with PBS, and exchanged into media containing phenol red-free DMEM and 4% FBS in the absence (control sample) or the presence (experimental sample) of 100 nM NanoBRET 618 fluorescent ligand (Promega). Cells were then treated with an increasing dose of OF-1. Five minutes prior to reading, NanoBRET furimazine substrate (Promega) was added to both control and experimental samples and plates were read on a CLARIOstar (BMG) equipped with 450/80 nm bandpass and 610 nm longpass filters with a 0.5 sec reading setting.  A corrected BRET ratio was calculated and is defined as the ratio of the emission at 610 nm/450 nm for experimental samples (i.e. those treated with NanoBRET fluorescent ligand) subtracted by and the emission at 610 nm/450 nm for control samples (not treated with NanoBRET fluorescent ligand). BRET ratios are expressed as milliBRET units (mBU), where 1 mBU corresponds to the corrected BRET ratio multiplied by 1000. Relative IC50 values were estimated by non-linear regression analysis of (log) concentration of each inhibitor versus milliBRET ratios (GraphPad Prism).

Human osteoclast differentiation

Primary human peripheral blood mononuclear cells (PBMCs) were collected from a Histopaque generated buffy coat after gradient centrifugation at 20 min and 500g, brakes off. The CD14+ monocyte fraction was obtained by on-column CD14+-MACS bead isolation, washed twice with MACS buffer, and seeded at a density of 50 000 c/mL in αMEM/10%FCS supplemented with 25 ng/mL MCSF. After 6 days at 37 °C, 5% CO2 treatment with NI-57 with and without 50 ng/mL RANKL was started. Media were changed with fresh compound every 3−4 days. After 14−21 days, cells were fixed and stained. IF was performed with VNR (red), F-Actin (green) and DAPI to visualize the possible bone-resorbing cells

LP99 A chemical probe for BRD9 and BRD7

This probe is available from Cayman Chemical and Tocris.

Its negative control (ent-LP99) is available for purchase from Tocris.

overview
Probe Negative control

 

LP99

 

2S,3R-Enantiomer

Biology of the BRD7 and BRD9 Bromodomains

BRD7 and BRD9 are related bromodomain- containing proteins that form a small sub-branch of the bromodomain family tree [1]. Human BRD9 contains a single bromodomain and has five isoforms that are produced by alternative splicing. Little is known about BRD9 function; BRD7 has been reported to act both as coactivator, for example for some p53 target genes and as corepressor, negatively regulating the GSK3B phosphotransferase activity. Both proteins have been implicated in chromatin remodelling as part of the SWI/SNF complex. BRD7 has been described as transcriptional corepressor that down-regulates the expression of target genes. Its binding to promoters also leads to increased histone H3 acetylation at 'Lys-9' (H3K9ac).

LP99

LP99, a BRD7/9 specific inhibitor, is a result of collaboration with Professor Darren J. Dixon at the University of Oxford [2]

Chemical structure of the active enantiomer (2R, 3S)-LP99. The enantiomer (2S, 3R)-LP99 is inactive against BRD9. The chiral centres are highlighted by a *.

Co-crystal structure

The co-crystal structure of LP99 (yellow) with BRD9 BRD has been solved, click on the 'Co-Crystal structures' tab above for more details.

Potency Against Target Family

LP99 is a potent binder to BRD9 with a KD = 99 nM as shown by ITC and was found to bind to the family member BRD7 with 10 fold lower affinity. The importance of chirality and configuration in this work is highlighted by the fact that the enantiomer of LP99, (2S, 3R)-LP99 showed no detectable binding to BRD9 by ITC.

This binding affinity was confirmed by HT-FRET where LP99 has an IC50 of 325nM

Selectivity


P. Clark et al, Angewandte Chemie Int. Ed. 2015
LP99 is a potent binder to BRD9 with a KD = 99 nM as shown by ITC and was found to bind to the family member BRD7 with 10 fold lower affinity. The importance of chirality and configuration in this work is highlighted by the fact that the enantiomer of LP99, (2S, 3R)-LP99 showed no detectable binding to BRD9 by ITC.

This binding affinity was confirmed by HT-FRET where LP99 has an IC50 of 325nM

Selectivity Beyond Target Family

LP99 was found to be inactive vs 55 receptors and ion channels (CEREP panel) at 10 µM, 66% antagonist binding inhibition to NK3 was the most potent activity measured. 

Cellular Activity

Cellular assays (FRAP, NanoBRET) demonstrate that the BRD7/9 inhibitor LP99 is able to disrupt the binding of BRD7 and BRD9 to chromatin in cells. Additionally, no cytotoxicity in U2OS cells was observed at 33 µM

properties

N-((2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxo-1,2-dihydroquinolin-7-yl)-6-oxopiperidin-3-yl)-2-methylpropane-1-sulfonamide

For SDF click here

Physical and chemical properties
Molecular weight516.05
Molecular formulaC26H30ClN3O4S
IUPAC nameN-((2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxo-1,2-dihydroquinolin-7-yl)-6-oxopiperidin-3-yl)-2-methylpropane-1-sulfonamide
logP4.75
PSA86.79 
No. of chiral centres2
No. of rotatable bonds4
No. of hydrogen bond acceptors9
No. of hydrogen bond donors1
StorageStable as solid in the dark at -20°C. NB making aliquots rather than freeze-thawing is recommended
DissolutionSoluble in DMSO at least up to ???
selectivity profile

Potency against Target

ITC

LP99 is a potent binder to BRD9 with a KD = 99 nM as shown by ITC. This binding is entirely driven by enthalpic interactions (ΔH=-11 kcal/mol), with a net loss in entropy upon binding (TΔS=-2.0 kcal/mol), which is consistent with a number of specific interactions with the protein. LP99 was found to bind to the family member BRD7 with 10 fold lower affinity. The importance of chirality and configuration in this work is highlighted by the fact that the enantiomer of LP99 showed no detectable binding to BRD9 by ITC.

TR-FRET BRD9 Binding Assay

LP99 binds to BR9 with an IC50 of 325nM. The enantiomer (2S, 3R)-LP99 is inactive

Selectivity Within Target family

DSF screen

LP99 binds to BRD9 and BRD7 with high selectivity over other members of the Bromodomain family including members of the IV subfamily.

Selectivity Beyond Target Family

 

CEREP screen

in vitro potency
cell based assay data

FRAP

The cellular efficacy of LP99 on BRD9 was investigated using a fluorescence recovery after photo-bleaching (FRAP) assay [18].  LP99 was found to have a dose dependent effect on FRAP recovery time, with higher doses showing a t1/2 akin to that of cells expressing a N100F BRD9 mutant unable to bind histone proteins.

BRET

To measure this further, a bioluminescence resonance energy transfer (BRET) assay was performed. BRD7–and BRD9–NanoLuc luciferase fusion proteins and fluorescently labelled histone H3.3– and H4–HaloTag fusions were expressed in HEK293 cells.[19] The addition of LP99 decreased BRET for both BRD7 and BRD9 in both the H3.3 and H4 systems in a dose-dependent manner.

InteractionIC50 (uM)InteractionIC50 (uM)
BRD7-H3.33.7 ± 0.27 (4)BRD9-H3.35.1 ± 0.50 (4)
BRD7-H43.3 ± 0.20 (4)BRD9-H46.2 ± 0.59 (4)

Cytotoxicity tests in U2OS cells for 24 and 72 hours showed the inhibitor to be non-toxic at concentrations of <33 uM.

Cytotoxicity

Cytotoxicity tests in U2OS cells for 24 and 72 hours showed the inhibitor to be non-toxic at concentrations of <33 uM

references
  1. Bromodomains as therapeutic targets,
    Muller, S., Filippakopoulos, P., Knapp, S., Exp Rev Mol Med, 13, e29, (2011).
     
  2. LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor,
    Clark, P.G., Vieira, L.C., Tallant, C., Fedorov, O., Singleton, D.C., Rogers, C.M., Monteiro, O.P., Bennett, J.M., Baronio, R., Müller, S., Daniels, D.L., Méndez, J., Knapp, S., Brennan, P.E., Dixon, D.J.,  Angew Chem Int Ed Engl, 54, 6217 –6221 (2015)
     
  3. Selective inhibition of BET bromodomains
    Filippakopoulos, P.; Qi, J.; Picaud, S.; Shen, Y.; Smith, W.B.; Fedorov, O.; Morse, E.M.; Keates, T.; Hickman, T.T.; Felletar, I.; Philpott, M.; Munro, S.; McKeown, M.R.; Wang, Y.; Christie, A.L.; West, N.; Cameron, M.J.; Schwartz, B.; Heightman, T.D.; La Thangue, N.; French, C.A.; Wiest, O.; Kung, A.L.; Knapp, S.; Bradner, J. E.,Nature 468, (7327) 1067-1073 ( 2010)
     
  4. Assessing cellular efficacy of bromodomain inhibitors using fluorescence recovery after photobleaching
    Philpott, M.; Rogers, C.M.; Yapp, C.; Wells, C.; Lambert, J.P.; Strain‐Damerell, C.; Burgess‐Brown, N.A.; Gingras, A.C.; Knapp, S.; Muller, S.,Epigenetics & chromatin 7, 14 (2014)
pk properties
co-crystal structures

The co-crystal structure of LP99 with BRD9 has been solved with a resolution of 1.7 Å. The key features are

  • LP99 binds to BRD9 ε-N-acetylated lysine (Kac) binding pocket
  • LP99 forms hydrogen bonds contacts with the conserved asparagine N216 as well as Y222.
  • LP99 is stabilized by hydrophobic and aromatic residues in the Kac binding pocket.
synthetic schemes
materials and methods

Isothermal Titration Calorimetry

Experiments were carried out on a VP-ITC titration microcalorimeter from MicroCalTM, LLC (Northampton, MA). All experiments were carried out at 15 °C while stirring at 295 rpm, in ITC buffer (50 mM HEPES pH 7.4 at 25 °C, 150 mM NaCl). The injection syringe (250 µl) was loaded with a solution of the protein sample (300 µM protein for the BETs, 950 µM protein for CREBBP and 600 µM for WDR9(2), in ITC buffer). All titrations were conducted using an initial injection of 2 µl followed by 34 identical injections of 8 µl with a duration of 16 sec (per injection) and a spacing of 250 sec between injections. The heat of dilution was determined by independent titrations (protein into buffer) and was subtracted from the experimental data. The collected data were implicated in the MicroCalTM Origin software supplied with the instrument to yield enthalpies of binding (ΔH) and binding constants (KB) as previously described by Wiseman and coworkers50. Thermodynamic parameters were calculated (ΔG = ΔH - TΔS = -RTlnKB, where ΔG, ΔH and ΔS are the changes in free energy, enthalpy and entropy of binding respectively). In all cases a single binding site model was employed.

TR-FRET BRD9 Binding Assay Using the EPIgeneousTM Binding Domain Kit B

This procedure is intended to measure the interaction between the BRD9 bromodomain and a peptide modified by acetylation of 4 lysine residues and can be used to assay compounds which bind to the bromodomain and inhibit this interaction.   The assay uses a GST tagged BRD9 with anti-GST antibody conjugated Eu3+ cyrptate (donor) and a biotinylated peptide with Streptavidin conjugated XL-665 (acceptor).  When the donor and acceptor labels are in close proximity, by binding of the peptide by the bromodomain, the excitation of the donor (337 nm) triggers a Fluorescence Resonance Energy Transfer (FRET) to the acceptor which then fluoresces at specific wavelength (665 nm)


This assay was run using kit B from CisBio in accordance to manufacturer protocol.

 

strong>Differential Scanning Fluorimetry (DSF)

Thermal melting experiments were carried out using an Mx3005p Real Time PCR machine (Stratagene). Proteins were buffered in 10 mM HEPES pH 7.5, 500 mM NaCl and assayed in a 96-well plate at a final concentration of 2 µM in 20 µl volume. Compounds were added at a final concentration of 10 µM. SYPRO Orange (Molecular Probes) was added as a fluorescence probe at a dilution of 1:1000. Excitation and emission filters for the SYPRO-Orange dye were set to 465 nm and 590 nm, respectively. The temperature was raised with a step of 3 °C per minute from 25 °C to 96 °C and fluorescence readings were taken at each interval. Data was analysed as previously reported [3]

CEREP assay

LP99  (10 µM) was screened against a panel of 55 ligand receptors, ion channels and transports using an established and widely utilized commercial assay platform (ExpresSProfile; CEREP, Paris, FRANCE).

Fluorescence Recovery After Photobleaching (FRAP) Assay

FRAP studies were performed using U20S cells expressing full-length BRD9 protein fused with an N-terminal eGFP as previously described [4]. Six hours after transfection 2.5uM SAHA (to increase global histone acetylation) was added and LP99 was added  1 hour before imaging, which was carried out 24 hours after transfection. Percent inhibition was calculated between the DMSO treated (0%) and N100F expressing mutant (100%)

NanoLuciferase Bioluminescent Resonance Energy Transfer (NanoBRET) Assay

HEK293 cells (8x105) were plated in each well of a 6-well plate and co transfected with one acceptor, Histone H3.3-HaloTag (NM_002107) or Histone H4 HaloTag (P62805); and one donor NanoLuc-BRD9 (Q9H8M2) BRD domain amino acids 120-240 or NanoLuc-BRD7 (NM_001173984) BRD domain amino acids 120-237. The cells were collected 20 hours after transfection, washed with PBS and exchanged into media containing phenol red-free DMEM and 4% FBS in the absence (control) or presence of 100nM NanoBRET 618 fluorescent ligand (Promega). Cell density was adjusted to 2x105 cells/ml and then re-plated into a 96-well white plate (Corning Costar #3917). LP99 was added at final concentrations between 0 and 33 uM and the plates incubated for 18hr at 37˚C in the presence of 5% CO2. NanoBRET furimazine substrate (Promega) was added at a final concentration of 10 uM. Readings were performed within 5 minutes using CLARIOstar (BMG) equipped with 450/80 nm bandpass and 610 nm longpass filters with a 0.5 s reading setting. A corrected BRET ratio was calculated (defined as ratio of emission at 610 nm/450 nm for samples treated with NanoBRET fluorescent ligand and emission at 610 nm/450 nm for samples not treated with NanoBRET fluorescent ligand). BRET ratios expressed as milli-BRET units (mBU) where 1 mBU corresponds to the corrected BRET ratio x 1000.

Cytotoxicity Assay

U20S cells were harvested from exponential phase cultures and plated in a 96-well opaque flat bottomed plates at a cell density of 3 x 103 cells/well (100uL). Compounds were dissolved in DMSO at 10 mM serial dilutions performed. 5 uL of compound solution was added to each well and incubated for 24 or 72 hours at 37˚C in a humidified atmosphere containing CO2 (5%). 10 uL of WST-1 (Roche) was added and the plates returned to the incubator. Plates were read on a plate reader at 450 nm after 2 h for cells treated with LP99 for 24 h or after 1 h for cells treated with LP99 for 72 h. Results plotted as % of DMSO control.